July 2, 2018 5:43pm

A new month, quarter and new “rules” for investment – guidance, transparency and delivering on “promises”

The problem in the sector is that the “operational” truths have its “variants” as seen by some management(s)!

 

The magnifying lens will be more in focus!

 

It’s a duty and an honor to be the “canary in the (sectors) coal mine”!  I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths.

RMi is the source investors and traders need – it’s more than opinion, the facts and truth need to be recognized!

Want to know WHY, subscribe!


Henry’omics:

 

Sector stocks rose on Monday, the first trading day of the third quarter, led by strong gains in the oversold.

Volume was LOW, except in MiMedx (MDXG -$2.46), BTX ($0.00) with no price movement, BLUE (-$2.95) to the downside, ATHX (-$0.07) to the downside, OSIR (+$0.35) to the upside having experienced their own criminalities!

  • Is MiMedx Group (MDXG) the newest Osiris (OSIR) and will it (the channel stuffing and bad actors) spill over to its comparables …?

From the pre-open newsletter titled …“fear and apprehension. Anticipating a triple-digit drop in the market, two slow days with a mid-week holiday, low volume with a slight chance of pricing rectitude – what’s good about today (?), the IBB is UP +0.06% … One can BUY as the down-slide cheapens and let sector equities ripen until their overbought next week.”

I also stated, “What’s good about today – another birthday and even that is an “ug”! If equities are cheaper than a hot dog and tastes like a burger – I’d bite but, I am staying away from predicting!” As I follow-up on “The KEY for Q3 will be news as the summer months will reduce “eyes” on the sector other than SPECULATION!”

 

Of the 45 companies covered on Monday; 15 downside equities finished in a range of -$0.10 (AXGN) to -$2.46 (MDXG) while the 27 upside equities oscillated from +$0.10 to $3.58 with 3 flat close.

 

Daily analytics and metrics:

  • The Dow closed 35.77 points higher after dropping nearly 200 points earlier in the session.
  • The S&P 500 advanced 0.3% to 2,726.71.
  • The NASDAQ rose 0.8% to 7,567.69.

 

The advance/decline line scenario of 45 covered companies:   

  • The open was negative with an A/DL of 15/25 and 5 flats;
  • The mid-day flipped positive with an A/DL of 23/17 and 5 flats;
  • The close was positive with an A/DL of 21/15 and 3 flat;

 

The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market,

  • Monday traded at 15.6, down -3.05%

 

The iShares Russell 2000 (IWM) closed:

  • Monday was up +0.68%;

 

The iShares NASDAQ Biotechnology (IBB) closed:

  • Monday was up +0.79%

 

MY working trend (5 largest) lines:

… The greatest volume to the downside:  MDXG, GBT, ATHX, XON and BLUE

… Upside volume was weighted to:  VSTM, SGMO, BLFS, VCEL and CRSP

… Biggest $ downside:  BLUE (-$2.95), MDXG (-$2.46), GBT (-$2.30), VYGR (-$0.44) and ALNY (-$0.41)

… Best moves to the $ upside: ONCE (+$4.00), BLFGS (+$3.58), RGNX (+$2.40), RARE (+$1.44) and QURE (+$1.38)

… Flats:  RENE.L, CUR and BSTG

 

The weekly count - decliners versus gainers – new month:

……. look at the differences in decliners:

Monday’s decliners ranged from -0.20% <AXGN -$0.10> to -38.5% <MDXG -$2.46> in 15 equities;

Versus

… Look at the percentage’s (%) and spreads …

Monday’s gainers ranged from +0.04% <AST +$0.00> to +31.38% <BLFS +$3.58 > in 27 equities;

 

JULY session:

  • Monday closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.